The Half-Life of Truth: What Are Appropriate Time Horizons for Research Decisions?
暂无分享,去创建一个
[1] John D. Graham,et al. Going beyond the single number: Using probabilistic risk assessment to improve risk management , 1996 .
[2] M Sculpher,et al. A pilot study on the use of decision theory and value of information analysis as part of the NHS Health Technology Assessment programme. , 2004, Health technology assessment.
[3] A A Stinnett,et al. Net Health Benefits , 1998, Medical decision making : an international journal of the Society for Medical Decision Making.
[4] Kimberly M. Thompson,et al. The Value of Improved National Exposure Information for Perchloroethylene (Perc): A Case Study for Dry Cleaners , 1997 .
[5] Andrew R Willan,et al. Expected value of information and decision making in HTA. , 2007, Health economics.
[6] James O. Berger. Statistical Decision Theory , 1980 .
[7] H. Raiffa,et al. Applied Statistical Decision Theory. , 1961 .
[8] Julien Taieb,et al. Truth Survival in Clinical Research: An Evidence-Based Requiem? , 2002, Annals of Internal Medicine.
[9] K Claxton,et al. The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. , 1999, Journal of health economics.
[10] A E Ades,et al. Expected Value of Sample Information Calculations in Medical Decision Modeling , 2004, Medical decision making : an international journal of the Society for Medical Decision Making.
[11] M. Sculpher,et al. Decision Modelling for Health Economic Evaluation , 2006 .
[12] Fumie Yokota,et al. Value of Information Literature Analysis: A Review of Applications in Health Risk Management , 2004, Medical decision making : an international journal of the Society for Medical Decision Making.
[13] Ronald A. Howard,et al. Information Value Theory , 1966, IEEE Trans. Syst. Sci. Cybern..
[14] Alan Brennan,et al. Efficient computation of partial expected value of sample information using Bayesian approximation. , 2007, Journal of health economics.
[15] C. Platell,et al. Half-life of truth in surgical literature , 1997, The Lancet.
[16] Gordon B. Hazen,et al. Sensitivity Analysis and the Expected Value of Perfect Information , 1998, Medical decision making : an international journal of the Society for Medical Decision Making.
[17] James K. Hammitt,et al. Research Planning for Food Safety , 1989 .
[18] S. Palmer,et al. Incorporating option values into the economic evaluation of health care technologies. , 2000, Journal of health economics.
[19] Laura Bojke,et al. Priority setting for research in health care: An application of value of information analysis to glycoprotein IIb/IIIa antagonists in non-ST elevation acute coronary syndrome , 2006, International Journal of Technology Assessment in Health Care.
[20] Karl Claxton,et al. A Pilot Study of Value of Information Analysis to Support Research Recommendations for NICE , 2005 .
[21] Karl Claxton,et al. Establishing the cost-effectiveness of new pharmaceuticals under conditions of uncertainty--when is there sufficient evidence? , 2005, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[22] Howard Raiffa,et al. Decision analysis: introductory lectures on choices under uncertainty. 1968. , 1969, M.D.Computing.
[23] P Tappenden,et al. Methods for expected value of information analysis in complex health economic models: developments on the health economics of interferon-beta and glatiramer acetate for multiple sclerosis. , 2004, Health technology assessment.
[24] M. Weinstein,et al. Taking account of future technology in cost effectiveness analysis , 2004, BMJ : British Medical Journal.
[25] Stephen E. Palmera,et al. A COST-EFFECTIVENESS MODEL COMPARING ALTERNATIVE MANAGEMENT STRATEGIES FOR THE USE OF GLYCOPROTEIN IIB / IIIA ANTAGONISTS IN NON-ST-ELEVATION ACUTE CORONARY SYNDROME , 2007 .
[26] K Claxton,et al. An economic approach to clinical trial design and research priority-setting. , 1996, Health economics.
[27] Stacy A. Johnson,et al. A COST-EFFECTIVENESS MODEL COMPARING ALTERNATIVE MANAGEMENT STRATEGIES FOR THE USE OF GLYCOPROTEIN IIB/IIIA ANTAGONISTS IN NON-ST- ELEVATION ACUTE CORONARY SYNDROME , 2007 .